ADHD - Combined Type
Conditions
Brief summary
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Interventions
DRUGMethylphenidate
single dose of 10 mg or 15 mg
DRUGPlacebo
Matching placebo
Sponsors
National Institutes of Health (NIH)
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Intervention model description
This is a double-blind cross over of a single dose of methylphenidate (10mg or 15mg) and matching placebo.
Eligibility
Sex/Gender
ALL
Age
6 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* right handed
Exclusion criteria
* pregnant or breast feeding * past or current neurological disorder * non-ADHD cause of cognitive impairment * uncontrolled medical disorder * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * having an adverse reaction to methylphenidate, or other stimulant medication * having a contraindication to MRI * current smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BOLD signal during response inhibition | Approximately 90 minutes after dose | BOLD signal (brain activity during fMRI, arbitrary units) in the anterior cingulate cortex during response inhibition. |
| Glutamate level in the anterior cingulate cortex | Approximately 2 hours after dose | Glutamate level (measured by MRS, institutional units) in the anterior cingulate cortex. |
Countries
United States
Contacts
Primary ContactKristin L Bigos, PhD
Backup ContactRobyn Wiseman, BS
Outcome results
None listed